Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

News & Events

Large-scale study uncovers a single major genetic risk factor for fatal parasitic disease

Research has identified a critical genetic risk factor for a potentially fatal parasitic disease that affects up to 400 thousand people a year, mostly children.

News & Events

Infectious Disease & Vaccination Public Seminar

Hear the facts about vaccination and infectious disease from some of Australia's leading experts: Professor Jonathan Carapetis, Dr Peter Richmond

News & Events

Pneumonia rates improve in Aboriginal children

New research from The Kids for Child Health Research shows that the pneumococcal vaccine program has contributed to closing of the gap

News & Events

WANTED: 'Flu Busters

Hundreds of healthy volunteers are needed in Perth to test the effectiveness of a current 'flu vaccine.

News & Events

Bird flu vaccine produces promising results

An Australian-developed vaccine that's been trialed in Perth has been found to produce a strong immune response against the H5N1 bird flu virus.

News & Events

Meningitis study aims for fewer needles

Perth researchers are investigating a new combined vaccine to protect against three causes of potentially deadly bacterial meningitis.

Research

Association between Congenital Anomalies and Late-Onset Bacterial Infections in Neonates Admitted to Neonatal Intensive Care Units in Australia and New Zealand

Compromised neonatal intensive care unit neonates are at risk of acquiring late-onset infections (late-onset sepsis [LOS]). Neonates born with congenital anomalies could have an additional LOS risk. 

Research

A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months

Respiratory syncytial virus (RSV) causes serious illness in children. The Ad26.RSV.preF vaccine candidate was immunogenic with acceptable safety in a phase 1/2a study of RSV-seropositive children. Here, we assessed its safety and immunogenicity in RSV-seronegative children. 

Research

A phase I clinical trial assessing the safety, tolerability, and pharmacokinetics of inhaled ethanol in humans as a potential treatment for respiratory tract infections

Current treatments for respiratory infections are severely limited. Ethanol's unique properties including antimicrobial, immunomodulatory, and surfactant-like activity make it a promising candidate treatment for respiratory infections if it can be delivered safely to the airway by inhalation. Here, we explore the safety, tolerability, and pharmacokinetics of inhaled ethanol in a phase I clinical trial.

Research

Biases in Routine Influenza Surveillance Indicators Used to Monitor Infection Incidence and Recommendations for Improvement

Monitoring how the incidence of influenza infections changes over time is important for quantifying the transmission dynamics and clinical severity of influenza. Infection incidence is difficult to measure directly, and hence, other quantities which are more amenable to surveillance are used to monitor trends in infection levels, with the implicit assumption that they correlate with infection incidence.